News | October 31, 2025
BMS’ Cobenfy sees steady start, eyes stronger growth ahead
Cobenfy generated $43 million in third-quarter sales, up from $35 million in the second quarter
Cobenfy generated $43 million in third-quarter sales, up from $35 million in the second quarter
ADX-248, which replaces ADX-743, is being developed for the treatment of metabolic inflammation, including obesity and hypertriglyceridemia
Vitiligo, affecting over 90 per cent of patients in its non-segmental form, is characterized by symmetrical white patches on both sides of the body
Sotyktu continues to demonstrate consistent efficacy and safety across rheumatic conditions
The event will be attended by 35,000+ industry professionals
Telangana aims to increase the value of the Life Sciences economy from US$ 80 billion to US$ 250 billion by 2030
_256_384.jpg)
Tirzepatide is a prescription based the first and only dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
The acquisition centers on ImCheck’s lead Phase I/II program, ICT01, a first-in-class monoclonal antibody targeting BTN3A
The SELECT-SWITCH study, first head-to-head Phase 3b/4 trial, compared switching to Rinvoq versus switching to another TNF inhibitor
In this role, Neeraj will be responsible for crafting strategy, driving profitable growth through organic and inorganic models, expanding client base
Subscribe To Our Newsletter & Stay Updated
